

Contacts:

Chris Martin

Vice President, Public Relations

CMartin@DavidJamesGroup.com | 630-670-2745

Becky Bunn, MSc

IASLC Project Specialist

Becky.Bunn@IASLC.org | 720-254-9509

Aberdeen Medical Oncologist and Professor to be Honored for Lifetime Scientific Achievement in Lung Cancer Translational Research

The International Association for the Study of Lung Cancer to Present Mary J. Matthews Award to Keith Kerr

DENVER – Professor Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, Pathologist for Aberdeen University Medical School, will be recognized by The International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria. Dr. Kerr will accept the Mary J. Matthews Pathology/Translational Research Award, honoring his lifetime scientific achievements in pathology-translational research of thoracic malignancies.

Dr. Kerr is Honorary Professor of Pulmonary Pathology at Aberdeen University Medical School in Scotland, United Kingdom. Dr. Kerr has worked in diagnostic histopathology for more than 35 years, and he takes a special interest in thoracic pathology and thoracic medicine, particularly oncology. He is dedicated to lung cancer classification and treatment guidelines, and is currently helping to revise the British Thoracic Society's mesothelioma guidelines.

“Individuals such as Dr. Kerr are crucial in the advancement of the fight against lung cancer,” said Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC. “Through his work and involvement in organizations such as the IASLC, Dr. Kerr has made a strong impact in lung cancer research across the globe. Most recently, Dr. Kerr has been instrumental in our effort to better understand which patients will benefit from immunotherapy.”

Dr. Kerr has been an active member of the IASLC for 20 years and is currently serving a four-year term on the IASLC Board of Directors. He has also been a member of the British Thoracic Society for more than 30 years and serves as Pathology Chair for the European Thoracic Oncology Platform's Lungscape group, among involvement in other organizations.

Dr. Kerr is regularly invited as a speaker and faculty member at major international conferences, and he has delivered more than 200 presentations on pathology and thoracic oncology. He has coauthored four textbooks, written more than 15 book chapters, and published more than 120 peer-reviewed articles.



Dr. Kerr received his BSc in pathology with first-class honors in 1978, his MB ChB in 1981, followed by post graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained MRCPATH and FRCPath in 1998, and he was elected an honorary FRCP(Ed) in 2006.

Dr. Kerr will be honored on Dec. 4, 2016 at the Opening Plenary Session at the IASLC 17th WCLC in Vienna, Austria. The IASLC WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The IASLC 17th WCLC will take place in Vienna, Austria Dec. 4-7, 2016. For more information on the IASLC 17th WCLC, visit: <http://wclc2016.iaslc.org/>.

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. Organized under the theme of "Together Against Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit <http://wclc2016.iaslc.org/>.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.

###

